Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate

• Celldex Therapeutics Inc (NASDAQ: CLDX) has priced an underwritten public offering of around 5.9 million shares at .00 per share, representing a discount of about 6% from the last close price of $44.6 on Tuesday.

• Gross proceeds are expected to approximately $250 million.

• The Company previously announced to offer 5 million in shares.

• Underwriters have an option to purchase up to an additional 892,857 shares.

• Jefferies, SVB Leerink, Guggenheim Securities, and Cantor are acting as the joint book-running managers for the offering.

• LifeSci Capital LLC and H.C. Wainwright & Co. are acting as co-lead managers for the offering.

• Celldex will use the proceeds to fund the development of CDX-0159 and for general corporate purposes.

• The offering will close by July 16.

• Recently, the Company shared positive Phase 1b trial data of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism.

• Price Action: CLDX shares are down 2.65% at $43.42 premarket on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.